Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats

Experimental Neurology

Volumn 229, Issue 2, 2011, Pages 288-299

  Dupre, Kristin B ^a   Ostock, Corinne Y ^a   Eskow Jaunarajs, Karen L ^a   Button, Thomas ^a   Savage, Lisa M ^a   Wolf, William ^b   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

5 HT1A receptor; D1 receptor; Dyskinesia; Glutamate; L DOPA; Parkinson's disease

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3,4 DIHYDROXYPHENYLACETIC ACID; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BENSERAZIDE; GLUTAMIC ACID; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXIDOPAMINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DYSKINESIA; EXTRACELLULAR SPACE; GLUTAMATE BRAIN LEVEL; GLUTAMATE RELEASE; MALE; MEDIAL FOREBRAIN BUNDLE; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; BENZAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; GLUTAMIC ACID; LEVODOPA; MALE; MICRODIALYSIS; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN RECEPTOR AGONISTS;

EID: 79956095948     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.02.012     Document Type: Article

References (72)

1. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., Ferraro L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005, 58:193-199.
2. Aubert I., Guigoni C., Hakansson K., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
3. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., Chase T.N. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 2005, 20:932-936.
4. Bianchi L., Galeffi F., Bolam J.P., Della Corte L. The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur. J. Neurosci. 2003, 18:856-868.
5. Bibbiani F., Oh J.D., Kielaite A., Collins M.A., Smith C., Chase T.N. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp. Neurol. 2005, 196:422-429.
6. Bishop C., Taylor J.L., Kuhn D.M., Eskow K.L., Park J.Y., Walker P.D. MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci. 2006, 23:2669-2676.
7. Bishop C., Krolewski D.M., Eskow K.L., Barnum C.J., Dupre K.B., Deak T., Walker P.D. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats. J. Neurosci. Res. 2009, 87:1645-1658.
8. Buck K., Voehringer P., Ferger B. Site-specific action of L-3, 4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3, 4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats. Neuroscience 2010, 166:355-358.
9. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet P.J., Bédard P.J., Di Paolo T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:127-138.
10. Campbell B.M., Kreipke C.W., Walker P.D. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat. Neuroscience 2006, 137:505-517.
11. Cao X., Yasuda T., Uthayathas S., Watts R.L., Mouradian M.M., Mochizuki H., Papa S.M. Striatal overexpression of ΔFosB reproduces chronic levodopa-induced involuntary movements. J. Neurosci. 2010, 30:7335-7343.
12. Carey R.J., DePalma G., Damianopoulos E., Muller C.P., Huston J.P. The 5-HT1A receptor and behavioral stimulation in the rat: Effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology 2004, 177:46-54.
13. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
14. Carta A.R., Frau L., Pinna A., Morelli M. Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp. Neurol. 2010, 224:395-402.
15. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends Neurosci. 2007, 30:236-243.
16. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
17. Chase T.N., Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 2000, 23:S86-S91.
18. Corsi C., Pinna A., Gianfriddo M., Melani A., Morelli M., Pedata F. Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur. J. Pharmacol. 2003, 464:33-38.
19. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Beh. Brain Res. 2007, 179:76-89.
20. Delfino M., Kalisch R., Czisch M., et al. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 2007, 32:1911-1921.
21. Donzanti B.A., Yamamoto B.K. An improved and rapid HPLC-EC method for the isocratic separation of amino acid neurotransmitters from brain tissue and microdialysis perfusates. Life Sci. 1988, 43:913-922.
22. Dupre K.B., Eskow K.L., Negron G., Bishop C. The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 2007, 1158:135-143.
23. Dupre K.B., Eskow K.L., Barnum C.J., Bishop C. Striatal 5-HT1A receptor stimulation reduced D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
24. Dupre K.B., Eskow K.L., Steiniger A., Klioueva A., Negron G., Lormand L., Park J., Bishop C. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacol. (Berl) 2008, 199:99-108.
25. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharm. Biochem. Behav. 2007, 87:306-314.
26. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of LID in hemiparkinsonian rats. Synapse 2009, 63:610-620.
27. Ferré S., Giménez-Llort L., Artigas F., Martínez E. Motor activation in short- and long-term reserpinized mice: role of N-methyl-d-aspartate, dopamine D1 and dopamine D2 receptors. Eur. J. Pharmacol. 1994, 255:203-213.
28. Gerfen C.R., Miyachi S., Paletzki R., Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 2002, 22:5042-5054.
29. Gerfen C.R., Paletzki R., Worley P. Differences between dorsal and ventral striatum in drd1a dopamine receptor coupling of dopamine- and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase. J. Neurosci. 2008, 28:7113-7120.
30. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., Rascol O., Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord. 2007, 22:179-186.
31. Goodwin G.M., De Souza R.J., Green A.R., Heal D.J. The pharmacology of the behavioral and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Psychopharmacology 1987, 91:506-511.
32. Goodwin P., Starr B.S., Starr M.S. Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801. J. Neural Transm. Park. Dis. Dement. Sect. 1992, 4:15-26.
33. Guigoni C., Doudnikoff E., Li Q., Bloch B., Bezard E. Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol. Dis. 2007, 26:452-463.
34. Hu X.T., White F.J. Dopamine enhances glutamate-induced excitation of rat striatal neurons by cooperative activation of D1 and D2 class receptors. Neurosci. Lett. 1997, 224:61-65.
35. Huot P., Johnston T.H., Koprich J.B., Winkelmolen L., Fox S.H., Brotchie J.M. Regulation of cortical and striatal 5-HT(1A) receptors in the MPTP-lesioned macaque. Neurobiol. Aging 2010, ahead of print.
36. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist(R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J. Pharmacol. Exp. Ther. 2006, 319:1225-1234.
37. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 2005, 20:S11-S16.
38. Jonkers N., Sarre S., Ebinger G., Michotte Y. MK801 suppresses the l-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res. 2002, 926:149-155.
39. Kilpatrick I.C., Jones M.W., Phillipson O.T. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: An isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem. 1986, 46:1865-1876.
40. Kobylecki C., Cenci M.A., Crossman A.R., Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J. Neurochem. 2010, 114:499-511.
41. Lindefors N., Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci. Lett. 1990, 115:248-252.
42. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2010, 112:1465-1476.
43. Lundblad M., Anderson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
44. Marin C., Papa S., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 1996, 736:202-205.
45. Matsubara K., Shimizu K., Suno M., et al. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 2006, 1112:126-133.
46. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999, 88:1-16.
47. Mignon L., Wolf W.A. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacol. (Berl) 2002, 163:85-94.
48. Mignon L.J., Wolf W.A. 8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. NeuroReport 2005, 16:699-703.
49. Morgese M.G., Cassano T., Gaetani S., et al. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55, 212-2. Neurochem. Int. 2009, 54:56-64.
50. Nash J.E., Brotchie J.M. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 2000, 20:7782-7789.
51. Ouattara B., Hoyer D., Grégoire L., Morissette M., Gasparini F., Gomez-Mancilla B., Di Paolo T. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 2010, 167:1160-1167.
52. Pavese N., Evans A.H., Tai Y.F., et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease. Neurology 2006, 67:1612-1617.
53. Paxinos G., Watson W. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego. 4th ed.
54. Pett M.A. Nonparametric Statistics for Health Care Research: Statistics for Small Samples and Unusual Distributions 1997, SAGE Publications, Inc., Thousand Oaks, California.
55. Pollack A.E., Yates T.M. Prior dopamine D1 receptor stimulation is required to prime D2-mediated striatal fos expression in 6-hydroxydopamine-lesioned rats. Neuroscience 1999, 94:505-514.
56. Porras A., Mora F. Dopamine-glutamate-GABA interactions and ageing: studies in the striatum of the conscious rat. Eur. J. Neurosci. 1995, 7:2183-2188.
57. Radnikow G., Misgeld U. Dopamine D1 receptors facilitate GABAA synaptic currents in the rat substantia nigra pars reticulata. J. Neurosci. 1998, 18:2009-2016.
58. Rangel-Barajas C., Silva I., Garcia-Ramirez M., Sanchez-Lemus E., Floran L., Aceves J., Erlij D., Floran B. 6-OHDA-induced hemiparkinsonism and chronic l-DOPA treatment increase dopamine D1-stimulated [3H]-GABA release and [3H]-cAMP production in substantia nigra pars reticulata of the rat. Neuropharmacology 2008, 55:704-711.
59. Rascol O., Nutt J.G., Blin O., et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch. Neurol. 2001, 58:249-254.
60. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., Abdalla M. Development of dyskinesias in a 5-year trial of ropinirole and l-dopa. Mov. Disord. 2006, 21:1844-1850.
61. Reid M.S., Herrera-Marschitz M., Kehr J., Ungerstedt U. Striatal dopamine and glutamate release: effects of intranigral injections of substance P. Acta Physiol. Scand. 1990, 140:527-537.
62. Robelet S., Melon C., Guillet B., Salin P., Kerkerian-LeGoff L. Chronic l-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2004, 20:1255-1266.
63. Robinson S., Freeman P., Moore C., Touchon J.C., Krentz L., Meshul C.K. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp. Neurol. 2003, 180:74-87.
64. Rowley H.L., Martin K.F., Marsden C.A. Determination of in vivo amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation. J. Neurosci. Meth. 1995, 57:93-99.
65. Rylander D., Iderberg H., Li Q., et al. A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 2010, 39:352-361.
66. Taylor J.L., Bishop C., Ullrich T., Rice K.C., Walker P.D. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 2006, 50:761-768.
67. Tomiyama M., Kimura T., Maeda T., Kannari K., Matsunaga M., Baba M. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to l-DOPA in a rodent model of Parkinson's disease. Neurosci. Res. 2005, 52:185-194.
68. Weick B.G., Walters J.R. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses. Brain Res. 1986, 405:243-246.
69. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
70. Yamamoto B.K., Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 1992, 58:1736-1742.
71. Yamamoto N., Pierce R.C., Soghomonian J.J. Subchronic administration of l-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata. Brain Res. 2006, 1123:196-200.
72. Yu H., Lewander T. Pharmacokinetic and pharmacodynamic studies of (R)-8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur. Neuropsychopharmacol. 1997, 7:165-172.